Loading clinical trials...

Optimizing Reperfusion to Improve Outcomes and Neurologic Function | Clinical Trials | Clareo Health

RECRUITINGPHASE2/PHASE3

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of JX10 in Acute Ischemic Stroke With Late Presentations

NCT06990867•Corxel Pharmaceuticals

View on ClinicalTrials.gov

Summary

The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS. During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥ 18 and ≤ 90 years old.
•2. Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA).
•3. Radiographic evidence of salvageable tissue.
•4. Pre-treatment score of NIHSS ≥ 5.

Exclusion Criteria

•1. Radiographic findings pre-randomization of any of the following:
•1. Large core infarction, or
•2. Occlusion in more than 1 vascular territory, or
•3. Significant mass effect or clinically significant cerebral edema, or
•4. Evidence of acute intracranial or extracranial hemorrhage, intracranial tumor (except small meningioma), neoplasm, or arteriovenous malformation), or
•5. Clinical history, past imaging, or clinical judgement suggests that the intracranial occlusion is chronic.
•2. Medical history or active clinically significant bleeding, lesions, or conditions (at the investigator's judgement) considered to be of significant risk for major bleeding.
•3. Severe, uncontrolled hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that cannot be controlled with antihypertensive therapy.
•4. Known bleeding diathesis (hereditary or acquired) or any significant coagulopathy. Specifically, platelet count \< 100,000/μL, international normalized ratio \> 1.7, aPTT \> 40 seconds, or prothrombin time \> 15 seconds.
•5. Major trauma, surgery, or invasive procedures.
+2 more criteria

Locations (83)

Corxel Investigational Site

Long Beach, California, United States

Corxel Investigational Site

Sacramento, California, United States

Corxel Investigational Site

Colorado Springs, Colorado, United States

Corxel Investigational Site

Washington D.C., District of Columbia, United States

Corxel Investigational Site

Delray Beach, Florida, United States

Corxel Investigational Site

Chicago, Illinois, United States

Corxel Investigational Site

Wichita, Kansas, United States

Corxel Investigational Site

Baltimore, Maryland, United States

Corxel Investigational Site

Kalamazoo, Michigan, United States

Corxel Investigational Site

Traverse City, Michigan, United States

Key Dates

Start Date

May 15, 2025

Primary Completion Date

October 31, 2029

Completion Date

December 31, 2029

Last Updated

March 13, 2026

Enrollment

740

ESTIMATED participants

Conditions

Acute Ischemic Stroke

Interventions

JX10

DRUG

Placebo

DRUG

Contacts

Corxel Pharmaceuticals Study Information Center

CONTACT

201-268-3723 Information.center@corxelbio.com

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

NCT07253181

Acute Ischemic StrokeLarge Vessel Occlusion+1 more

View study

RECRUITINGNA

Prospective Randomized Observer Blinded Single Center Study Comparing 90-day Functional Outcome in Patients Who Received Intravenous Propofol Infusion Versus Inhalational Sevoflurane for General Anesthesia During Mechanical Thrombectomy in Patients Who Suffered From Acute Ischemic Stroke

NCT07001267

Acute Ischemic Stroke Patients

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 13, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

Inclusion Criteria

Exclusion Criteria

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

Prospective Randomized Observer Blinded Single Center Study Comparing 90-day Functional Outcome in Patients Who Received Intravenous Propofol Infusion Versus Inhalational Sevoflurane for General Anesthesia During Mechanical Thrombectomy in Patients Who Suffered From Acute Ischemic Stroke

Brain, Blood And Clot or Tissue Registry And Collaboration

A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.

Radiohistological Correlation of Thrombohemorrhagic Remodeling in the Acute Phase of Ischemic Stroke Managed by Decompressive Hemicraniectomy

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke